Accelerating Drug Development Through Collaboration: The Hepatitis C Drug Development Advisory Group

E-ISSN： 1532-6535|96|2|162-165

ISSN： 0009-9236

Source： CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.96, Iss.2, 2014-08, pp. : 162-165

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Development of a cross-pharmaceutical database: a paradigm change for accelerating the drug-development process

By Alphs Larry

Clinical Investigation, Vol. 3, Iss. 8, 2013-08 ,pp. : 715-717

Future Science

Access to resources Recommend Favorite

Acceleration of Drug Development: A Collaboration of Many Stakeholders

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 93, Iss. 6, 2013-06 ,pp. : 455-459

John Wiley & Sons Inc

Access to resources Recommend Favorite

3. New Drug Development Group (AWO)

Oncology Research and Treatment, Vol. 21, Iss. 3, 1998-07 ,pp. : 63-64

Karger

Access to resources Recommend Favorite

Development and validation of a “capture‐fusion” model to study drug sensitivity of patient‐derived hepatitis C

HEPATOLOGY, Vol. 61, Iss. 4, 2015-04 ,pp. : 1192-1204

John Wiley & Sons Inc

Access to resources Recommend Favorite

Good science behind hepatitis C virus antiviral drug development: Necessary but not sufficient

HEPATOLOGY, Vol. 46, Iss. 5, 2007-11 ,pp. : 1317-1318

John Wiley & Sons Inc

Access to resources Recommend Favorite